Insulin to Account for 32% of the Indian Diabetes Medication Market by 2018
A new report expects the Indian insulin market to grow at a CAGR of 19% during 2013-2018.
New Delhi, India, April 27, 2013 --(PR.com)-- IMARC Group, one of the world’s leading research and advisory firms, expects the total market for insulin in India to grow at a CAGR of 19% during 2013-2018. Findings from its latest report entitled “Indian Diabetes Market Report: Epidemiology, Patients, Prevalence, Oral Anti-diabetics, Insulin and Diagnostics” suggests that by 2018, insulin is expected to account for 32% of the entire diabetes medication market in India.
According to the report, the market for both oral anti-diabetics and insulin are experiencing robust growth. The report cites increasing sedentary lifestyles, lack of physical activity, obesity, stress and consumption of diets rich in fat, sugar and calories as the catalysts in driving the prevalence of diabetes in India. According to an analyst at IMARC Group, “India’s rapid economic growth in the last few decades has led to a rapid urbanization in the country. Between 1991 and 2011, the proportion of people living in urban India rose from 26% to 31%; a trend that is predicted to increase at a faster pace in the coming years. Increased prosperity has brought an increase in sedentary lifestyles and western diets. As a result, the prevalence of diabetes in the urban regions has been much faster compared to the rural regions.”
IMARC’s new report “Indian Diabetes Market Report: Epidemiology, Patients, Prevalence, Oral Anti-diabetics, Insulin and Diagnostics” provides an analytical and statistical insight into the Indian diabetes market. The report provides both current and future trends in the prevalence, demographical breakup, diagnosis and treatment of diabetes in India. The report has segmented the Indian diabetes market into three segments - Oral Anti-diabetics, Insulin and Diabetes Diagnostics. For each of the aforementioned categories, the report provides historical and future market sales, performance of key classes and the performance of top players.
To buy the complete report or to get a free sample, please contact:
IMARC Group Asia
Email: apac@imarcgroup.com
Phone: +91-120-415-5099
IMARC Group North America
Email: america@imarcgroup.com
Phone: +1-631-791-1145
IMARC Group Europe, Middle East & Africa
Email:ema@imarcgroup.com
Phone: +44-702-409-7331
To know more please visit: http://www.imarcgroup.com/india-diabetes/
According to the report, the market for both oral anti-diabetics and insulin are experiencing robust growth. The report cites increasing sedentary lifestyles, lack of physical activity, obesity, stress and consumption of diets rich in fat, sugar and calories as the catalysts in driving the prevalence of diabetes in India. According to an analyst at IMARC Group, “India’s rapid economic growth in the last few decades has led to a rapid urbanization in the country. Between 1991 and 2011, the proportion of people living in urban India rose from 26% to 31%; a trend that is predicted to increase at a faster pace in the coming years. Increased prosperity has brought an increase in sedentary lifestyles and western diets. As a result, the prevalence of diabetes in the urban regions has been much faster compared to the rural regions.”
IMARC’s new report “Indian Diabetes Market Report: Epidemiology, Patients, Prevalence, Oral Anti-diabetics, Insulin and Diagnostics” provides an analytical and statistical insight into the Indian diabetes market. The report provides both current and future trends in the prevalence, demographical breakup, diagnosis and treatment of diabetes in India. The report has segmented the Indian diabetes market into three segments - Oral Anti-diabetics, Insulin and Diabetes Diagnostics. For each of the aforementioned categories, the report provides historical and future market sales, performance of key classes and the performance of top players.
To buy the complete report or to get a free sample, please contact:
IMARC Group Asia
Email: apac@imarcgroup.com
Phone: +91-120-415-5099
IMARC Group North America
Email: america@imarcgroup.com
Phone: +1-631-791-1145
IMARC Group Europe, Middle East & Africa
Email:ema@imarcgroup.com
Phone: +44-702-409-7331
To know more please visit: http://www.imarcgroup.com/india-diabetes/
Contact
IMARC Group
Krishna Sharma
911204155099
www.imarcgroup.com
Krishna Sharma
911204155099
www.imarcgroup.com
Contact
Categories